Emergent BioSolutions Inc. (0IGA.L)
USD 8.5
(-3.22%)
USD 8.5
(-3.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.04 Billion USD | -6.39% |
| 2022 | 1.12 Billion USD | -37.47% |
| 2021 | 1.79 Billion USD | 15.26% |
| 2020 | 1.55 Billion USD | 40.63% |
| 2019 | 1.1 Billion USD | 41.36% |
| 2018 | 782.4 Million USD | 39.5% |
| 2017 | 560.87 Million USD | 14.75% |
| 2016 | 488.78 Million USD | -6.5% |
| 2015 | 522.78 Million USD | 16.14% |
| 2014 | 450.13 Million USD | 43.93% |
| 2013 | 312.74 Million USD | 10.95% |
| 2012 | 281.88 Million USD | 3.11% |
| 2011 | 273.38 Million USD | -4.47% |
| 2010 | 286.17 Million USD | 21.89% |
| 2009 | 234.78 Million USD | 31.49% |
| 2008 | 178.55 Million USD | -2.38% |
| 2007 | 182.91 Million USD | 19.76% |
| 2006 | 152.73 Million USD | 16.87% |
| 2005 | 130.68 Million USD | 56.52% |
| 2004 | 83.49 Million USD | 49.71% |
| 2003 | 55.76 Million USD | -28.99% |
| 2002 | 78.54 Million USD | 73.35% |
| 2001 | 45.3 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 254.7 Million USD | -15.21% |
| 2024 Q1 | 300.4 Million USD | 8.6% |
| 2023 Q3 | 270.5 Million USD | -19.95% |
| 2023 Q4 | 276.6 Million USD | 2.26% |
| 2023 Q2 | 337.9 Million USD | 104.66% |
| 2023 Q1 | 165.1 Million USD | -50.08% |
| 2023 FY | 1.04 Billion USD | -6.39% |
| 2022 Q2 | 242.7 Million USD | -21.07% |
| 2022 Q1 | 307.5 Million USD | -57.48% |
| 2022 FY | 1.12 Billion USD | -37.47% |
| 2022 Q3 | 240 Million USD | -1.11% |
| 2022 Q4 | 330.7 Million USD | 37.79% |
| 2021 FY | 1.79 Billion USD | 15.26% |
| 2021 Q1 | 343 Million USD | -41.17% |
| 2021 Q2 | 397.5 Million USD | 15.89% |
| 2021 Q3 | 329 Million USD | -17.23% |
| 2021 Q4 | 723.2 Million USD | 119.82% |
| 2020 Q2 | 394.7 Million USD | 105.04% |
| 2020 Q3 | 385.2 Million USD | -2.41% |
| 2020 Q1 | 192.5 Million USD | -46.59% |
| 2020 Q4 | 583 Million USD | 51.35% |
| 2020 FY | 1.55 Billion USD | 40.63% |
| 2019 Q1 | 190.6 Million USD | -29.59% |
| 2019 FY | 1.1 Billion USD | 41.36% |
| 2019 Q2 | 243.2 Million USD | 27.6% |
| 2019 Q3 | 311.8 Million USD | 28.21% |
| 2019 Q4 | 360.4 Million USD | 15.59% |
| 2018 Q3 | 173.65 Million USD | -21.14% |
| 2018 Q2 | 220.2 Million USD | 86.9% |
| 2018 FY | 782.4 Million USD | 39.5% |
| 2018 Q1 | 117.81 Million USD | -39.21% |
| 2018 Q4 | 270.7 Million USD | 55.89% |
| 2017 Q2 | 100.77 Million USD | -13.77% |
| 2017 FY | 560.87 Million USD | 14.75% |
| 2017 Q1 | 116.85 Million USD | -22.95% |
| 2017 Q4 | 193.8 Million USD | 29.7% |
| 2017 Q3 | 149.43 Million USD | 48.29% |
| 2016 Q3 | 142.91 Million USD | 40.82% |
| 2016 Q1 | 111 Million USD | -33.97% |
| 2016 FY | 488.78 Million USD | -6.5% |
| 2016 Q4 | 151.66 Million USD | 6.12% |
| 2016 Q2 | 101.48 Million USD | -8.57% |
| 2015 FY | 522.78 Million USD | 16.14% |
| 2015 Q4 | 168.1 Million USD | 1.92% |
| 2015 Q3 | 164.94 Million USD | 30.79% |
| 2015 Q2 | 126.11 Million USD | 98.19% |
| 2015 Q1 | 63.63 Million USD | -57.0% |
| 2014 Q3 | 137.95 Million USD | 25.04% |
| 2014 Q4 | 147.97 Million USD | 7.26% |
| 2014 FY | 450.13 Million USD | 43.93% |
| 2014 Q1 | 53.88 Million USD | -45.08% |
| 2014 Q2 | 110.32 Million USD | 104.75% |
| 2013 Q3 | 89.1 Million USD | 8.09% |
| 2013 FY | 312.74 Million USD | 10.95% |
| 2013 Q1 | 43.1 Million USD | -54.44% |
| 2013 Q4 | 98.1 Million USD | 10.11% |
| 2013 Q2 | 82.43 Million USD | 91.27% |
| 2012 FY | 281.88 Million USD | 3.11% |
| 2012 Q4 | 94.6 Million USD | 42.07% |
| 2012 Q3 | 66.59 Million USD | -5.38% |
| 2012 Q2 | 70.37 Million USD | 39.89% |
| 2012 Q1 | 50.31 Million USD | -53.39% |
| 2011 Q4 | 107.94 Million USD | 83.7% |
| 2011 Q1 | 18.53 Million USD | -82.05% |
| 2011 Q2 | 88.14 Million USD | 375.59% |
| 2011 Q3 | 58.76 Million USD | -33.33% |
| 2011 FY | 273.38 Million USD | -4.47% |
| 2010 Q2 | 62.13 Million USD | 32.77% |
| 2010 Q1 | 46.8 Million USD | -13.02% |
| 2010 Q3 | 73.98 Million USD | 19.07% |
| 2010 Q4 | 103.24 Million USD | 39.55% |
| 2010 FY | 286.17 Million USD | 21.89% |
| 2009 Q2 | 73.19 Million USD | 13.44% |
| 2009 FY | 234.78 Million USD | 31.49% |
| 2009 Q4 | 53.8 Million USD | 24.34% |
| 2009 Q3 | 43.27 Million USD | -40.88% |
| 2009 Q1 | 64.51 Million USD | 80.47% |
| 2008 Q1 | 42.72 Million USD | -52.34% |
| 2008 FY | 178.55 Million USD | -2.38% |
| 2008 Q4 | 35.75 Million USD | -36.84% |
| 2008 Q3 | 56.59 Million USD | 30.16% |
| 2008 Q2 | 43.48 Million USD | 1.79% |
| 2007 Q3 | 43.64 Million USD | 88.23% |
| 2007 Q4 | 89.63 Million USD | 105.38% |
| 2007 Q1 | 26.44 Million USD | -69.56% |
| 2007 FY | 182.91 Million USD | 19.76% |
| 2007 Q2 | 23.18 Million USD | -12.33% |
| 2006 Q3 | 21.94 Million USD | 0.0% |
| 2006 Q4 | 86.88 Million USD | 295.89% |
| 2006 FY | 152.73 Million USD | 16.87% |
| 2006 Q2 | 21.94 Million USD | 0.0% |
| 2006 Q1 | 21.94 Million USD | -49.88% |
| 2005 Q3 | 28.96 Million USD | 0.0% |
| 2005 Q2 | 28.96 Million USD | 0.0% |
| 2005 Q1 | 28.96 Million USD | 38.78% |
| 2005 FY | 130.68 Million USD | 56.52% |
| 2005 Q4 | 43.78 Million USD | 51.17% |
| 2004 Q3 | 20.87 Million USD | 0.0% |
| 2004 Q1 | 20.87 Million USD | 0.0% |
| 2004 Q2 | 20.87 Million USD | 0.0% |
| 2004 FY | 83.49 Million USD | 49.71% |
| 2004 Q4 | 20.87 Million USD | -0.0% |
| 2003 FY | 55.76 Million USD | -28.99% |
| 2002 FY | 78.54 Million USD | 73.35% |
| 2001 Q1 | 307.5 Million USD | -7.02% |
| 2001 Q2 | 337.9 Million USD | 9.89% |
| 2001 Q3 | 329 Million USD | -2.63% |
| 2001 FY | 45.3 Million USD | 0.0% |
| 2001 Q4 | 330.7 Million USD | 0.52% |
| 2000 Q4 | 330.7 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -1243.138% |
| Dynavax Technologies Corporation | 232.28 Million USD | -351.732% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -72.718% |
| Perrigo Company plc | 4.65 Billion USD | 77.462% |
| Illumina, Inc. | 4.5 Billion USD | 76.703% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 97.552% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -88150.631% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.289% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 92.997% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -725.934% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 92.001% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 64.508% |
| Biogen Inc. | 9.83 Billion USD | 89.332% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -495.408% |
| Evolus, Inc. | 202.08 Million USD | -419.237% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -4904.292% |
| bluebird bio, Inc. | 29.49 Million USD | -3457.311% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -801.972% |
| FibroGen, Inc. | 147.75 Million USD | -610.177% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 84.644% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 15876.575% |
| Geron Corporation | 237 Thousand USD | -442642.616% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 42.608% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -162.748% |
| Myriad Genetics, Inc. | 678.4 Million USD | -54.673% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -2792.626% |
| Zoetis Inc. | 8.54 Billion USD | 87.719% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -29880.0% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 72.302% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 56.627% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 89.368% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -33.22% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -12139.589% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -1064.311% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -287.768% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -3257.867% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 15.606% |
| OPKO Health, Inc. | 863.49 Million USD | -21.518% |
| Exelixis, Inc. | 1.83 Billion USD | 42.668% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 44.396% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -117.528% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -6523.114% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -320.763% |
| Insmed Incorporated | 305.2 Million USD | -243.798% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -26.536% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -3811.941% |
| TG Therapeutics, Inc. | 233.66 Million USD | -349.067% |
| Incyte Corporation | 3.69 Billion USD | 71.607% |